This site is intended for health professionals only


Regulator warns on congential heart defects with SSRI



By Nigel Praities

The UK medicines regulator has warned of a ‘possible small risk' of congenital heart defects when prescribing the selective-serotonin reuptake inhibitor fluoxetine.

The Medicines and Healthcare products Regulatory Agency said they had looked at the evidence from a number of studies and had calculated that fluoxetine doubles the background rate of congenital heart defects.

The background incidence of congenital cardiac defects is approximately 1/100 and the MHRA estimates to increase to less than 2/100 pregnancies with fluoxetine prescription.

The MHRA said that a class effect with SSRIs on heart formation in utero ‘could not be excluded' and recommended GPs were mindful of this when prescribing the drugs.

A MHRA statement said: ‘When prescribing fluoxetine to treat depression during pregnancy, prescribers should be aware that there may be a small increased risk of congenital cardiac defects in infants exposed in early pregnancy, similar to that seen with paroxetine.'

Drug Safety Update; 3(8); pg. 4

Regulator warns 'small risk' of congential heart defects with fluoxetine MHRA advice

• When prescribing fluoxetine to treat depression during pregnancy, prescribers should be aware that there may be a small increased risk of congenital cardiac defects in infants exposed in early pregnancy, similar
to that seen with paroxetine

• There are insufficient data to draw conclusions on the risk of congenital anomalies with other SSRIs, but the possibility of a class effect cannot be excluded

• The potential increased risk should be considered in the context of the benefits of treating depression in pregnancy

Complete relevant Ear, nose and throat CPD modules on Pulse Learning by registering for free, or upgrade to a premium membership for full access at only £89 a year.